Search

Your search keyword '"Dijkstra, Frederika"' showing total 4 results
Start Over Author "Dijkstra, Frederika" Journal influenza and other respiratory viruses
4 results on '"Dijkstra, Frederika"'

1. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children

Author

Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, I-MOVE/I-MOVE+ study team, EpiConcept [Paris], National Centre for Microbiology [Madrid], Instituto de Salud Carlos III [Madrid] (ISC), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Department for Infectious Disease Epidemiology [Berlin], Robert Koch Institute [Berlin] (RKI), Department of Infectious Diseases [Rome, Italy], Istituto Superiore di Sanita, CIBER de Epidemiología y Salud Pública (CIBERESP), National Centre for Epidemiology. CIBERNED. Carlos III Institute of Health, Madrid, Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC)-Instituto de Salud Carlos III [Madrid] (ISC), National Centre for Epidemiology [Budapest], Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), National Institute of Public Health - National Institute of Hygiene [Poland], National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Croatian Institute of Public Health [Zagreb] (CIPH), Génétique moléculaire des virus à ARN ((U-Pasteur_ 2 / UMR_3569)), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), National Reference Centre for Influenza [Berlin], European Centre for Disease Prevention and Control (ECDC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Istituto Superiore di Sanità (ISS), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Instituto de Salud Carlos III (ISC), CIBER de Enfermedades Neurodegenerativas (CIBERNED), National Institute of Public Health – National Institute of Hygiene [Varsovie], Instituto Nacional de Saúde Doutor Ricardo Jorge [Lisboa], European Centre for Disease Prevention and Control, Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, and D'Agaro, Pierlanfranco

Subjects
Male, 0301 basic medicine, Epidemiology, viruses, Influenza B viru, vaccine effectivene, Efetividade da Vacina Antigripal, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Influenza A Virus, Medicine, 030212 general & internal medicine, Child, Vaccine effectiveness, I-MOVE+, virus diseases, Middle Aged, multicentre study, 3. Good health, Europe, Infectious Diseases, Influenza Vaccines, Child, Preschool, Original Article, Female, Case-Control Studie, influenza, Human, Adult, Pulmonary and Respiratory Medicine, Trivalent influenza vaccine, Lineage (genetic), Adolescent, Influenza vaccine, case-control study, 030106 microbiology, Influenza season, Young Adult, 03 medical and health sciences, Influenza, Human, Humans, I-MOVE, H1N1 Subtype, Vacina Antigripal, ddc:610, Preschool, Aged, vaccine effectiveness, case‐control study, business.industry, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Case-control study, Infant, Influenza a, Original Articles, influenza vaccine, Case-Control Studies, Influenza B virus, Case Control Study, Virology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, vaccine effe, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, 610 Medizin und Gesundheit, business
Abstract

BACKGROUND: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. METHODS: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. RESULTS: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. CONCLUSIONS: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. ECDC has contributed fund for the coordination and some study sites under the Framework contract no. ECDC/2014/026 for the individuals aged less than 65 years. The I‐MOVE/I‐MOVE+ study team is very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams and regional epidemiologists who have contributed to the study. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website http://www.gisaid.org. Sí

Published
2018

2. Absence of association between 2019‐20 influenza vaccination and COVID‐19: Results of the European I‐MOVE‐COVID‐19 primary care project, March‐August 2020

Author

Kissling, Esther, primary, Hooiveld, Mariëtte, additional, Brytting, Mia, additional, Vilcu, Ana‐Maria, additional, de Lange, Marit, additional, Martínez‐Baz, Iván, additional, Sigerson, Debbie, additional, Enkirch, Theresa, additional, Belhillil, Sylvie, additional, Meijer, Adam, additional, Castilla, Jesus, additional, William, Naoma, additional, Carnahan, AnnaSara, additional, Falchi, Alessandra, additional, Hendriksen, Janneke, additional, Casado, Itziar, additional, Murray, Josie, additional, Enouf, Vincent, additional, Dijkstra, Frederika, additional, Marques, Diogo F. P., additional, and Valenciano, Marta, additional

Published
2021
Full Text
View/download PDF

3. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.

Author

Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Oroszi B, Hooiveld M, Gomez V, Domegan L, Martínez-Baz I, Ilić M, Carnahan AS, Mihai ME, Martínez A, Goerlitz L, Enouf V, Horváth JK, Dijkstra F, Rodrigues AP, Bennett C, Trobajo-Sanmartín C, Mlinarić I, Latorre-Margalef N, Ivanciuc A, Lopez A, Dürrwald R, Falchi A, Túri G, Meijer A, Melo A, O'Donnell J, Castilla J, Vučina VV, Hagey TS, Lazar M, Kaczmarek M, Bacci S, and Kissling E

Subjects
Child, Humans, Europe epidemiology, Influenza A Virus, H3N2 Subtype genetics, Primary Health Care, Vaccine Efficacy, Infant, Newborn, Infant, Child, Preschool, Adolescent, Young Adult, Adult, Middle Aged, Influenza A virus, Influenza A Virus, H1N1 Subtype genetics, Influenza Vaccines, Influenza, Human epidemiology, Influenza, Human prevention & control
Abstract

Background: Influenza A(H3N2) viruses dominated early in the 2022-2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study., Materials and Methods: Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression., Results: We included 38 058 patients, of which 3786 were influenza A(H3N2), 1548 influenza A(H1N1)pdm09 and 3275 influenza B cases. Against influenza A(H3N2), VE was 36% (95% CI: 25-45) among all ages and ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25-49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95% CI: 35-56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46-65) and 79% (95% CI: 64-88) against clade 5a.2a.1. VE against influenza B was 76% (95% CI: 70-81); overall, 84%, 72% and 71% were among 0-14-year-olds, 15-64-year-olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197 mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73-85) and 90% (95% CI: 85-94) without this mutation., Conclusion: The 2022-2023 end-of-season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2)., Competing Interests: None., (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

4. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study.

Author

Kissling E, Pozo F, Martínez-Baz I, Buda S, Vilcu AM, Domegan L, Mazagatos C, Dijkstra F, Latorre-Margalef N, Kurečić Filipović S, Machado A, Lazar M, Casado I, Dürrwald R, van der Werf S, O'Donnell J, Linares Dopido JA, Meijer A, Riess M, Višekruna Vučina V, Rodrigues AP, Mihai ME, Castilla J, Goerlitz L, Falchi A, Connell J, Castrillejo D, Hooiveld M, Carnahan A, Ilić M, Guiomar R, Ivanciuc A, Maurel M, Omokanye A, and Valenciano M

Subjects
Humans, Case-Control Studies, Europe epidemiology, Influenza A Virus, H3N2 Subtype genetics, Primary Health Care, Vaccination, Vaccine Efficacy, Male, Female, Infant, Newborn, Infant, Child, Preschool, Child, Adolescent, Young Adult, Adult, Middle Aged, Aged, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human epidemiology, Influenza, Human prevention & control
Abstract

Background: In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE)., Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions., Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43-89) and 81% (95% CI: 45-93) among those aged 15-64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12-42) and 25% (95% CI: -41 to 61), 33% (95% CI: 14-49), and 26% (95% CI: -22 to 55) among those aged 0-14, 15-64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: -6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2., Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza., (© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results